NR2B Selective Antagonists for Depression via Piperidine Carbamate Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NR2B subtype selective NMDA receptor antagonists have limitations in pharmacokinetic performance, oral activity, and cardiovascular safety, which restrict their potential use in human drug therapy for depression and other clinical indications.
Innovation Solution
Development of chemical entities of Formula (I), where R1 and Z are defined, which act as NR2B subtype selective receptor antagonists, improving pharmacokinetic performance, oral activity, and in vitro and in vivo therapeutic safety indices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective NMDA receptor antagonists such as ketamine are used, then rapid onset antidepressant efficacy is achieved, but dissociative and psychogenic side effects are prominent
Solution Approach 1:
The patent applies segmentation by dividing the NMDA receptor into functional subtypes (NR2A, NR2B, NR2D) and developing antagonists that selectively target only the NR2B subtype. This selective antagonism preserves beneficial antidepressant effects while eliminating harmful dissociative side effects associated with non-selective NMDA receptor blockade.
Solution Approach 2:
The patent employs local quality by designing compounds with specific molecular structures (Formula I featuring piperidine carbamate and heterocyclic moieties) that confer selective affinity for NR2B-containing NMDA receptors. This structural specificity enables the drug to interact preferentially with NR2B subunits while sparing other NMDA receptor subtypes, thereby achieving selective therapeutic action.
2Object-affected harmful factors
If NR2B subtype selective NMDA receptor antagonists are developed, then dissociative side effects are diminished, but pharmacokinetic performance and oral activity are limited
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of the NR2B-selective antagonist (substituents R1-R6, ring structures) to optimize pharmacokinetic properties. These structural adjustments improve oral bioavailability, extend half-life, and enhance plasma protein binding while maintaining selective NR2B antagonism, thereby achieving reliable pharmacokinetic performance.
3Object-affected harmful factors
If NR2B subtype selective NMDA receptor antagonists are developed, then dissociative side effects are reduced, but cardiovascular safety and therapeutic safety index are limited
Solution Approach 1:
The patent applies the blessing in disguise principle by designing NR2B-selective antagonists that convert the potential harm of NMDA receptor blockade into beneficial therapeutic effects. By selectively targeting NR2B subunits in specific brain regions (prefrontal cortex, hippocampus) while sparing cardiovascular NMDA receptors, the compound achieves antidepressant efficacy without compromising cardiovascular safety, thus converting selective antagonism into a protective feature.
Data Source
AI summary
Disclosed are chemical entities of Formula (I), wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).